Recent news on Luxiq

Stiefel Laboratories Moves to Solidify, Enhance Its Leadership ...  -  Apr 23, 2007
PR Newswire (press release),5%); Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(TM) Cream; Olux(R) (clobetasol propionate) Foam,

Stiefel Laboratories Moves to Solidify, Enhance Its Leadership ...  -  Apr 23, 2007
PharmaLive.com (press release),5%); Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(TM) Cream; Olux(R) (clobetasol propionate) Foam,

Stiefel Laboratories, Inc. Appoints Richard J. MacKay Vice ...  -  Jan 30, 2007
PharmaLive.com (press release),...include Sarna(r), Duac(r) Topical Gel, MimyX(tm) Cream, Olux-E(r), Brevoxyl*Creamy Wash, Oilatum(r), Soriatane(r), Evoclin(r), Verdeso(tm) and Luxiq(r).

Stiefel Laboratories, Inc. Donates First Dermatology Ward in ...  -  Feb 2, 2007
Drug Newswire (press release),Duac(R) Topical Gel, MimyX(TM) Cream, Olux(R), Brevoxyl(R) Creamy Wash, Oilatum(R), Soriatane(R), Evoclin(TM), Verdeso(TM) and Luxiq(R).

Stiefel Laboratories, Inc. Completes Acquisition of Connetics ...  -  Dec 29, 2006
PharmaLive.com (press release),...include Sarna(R), Duac(R) Topical Gel, MimyX(TM) Cream, Olux(R), Brevoxyl(R)Creamy Wash, Oilatum(R), Soriatane(R), Evoclin(R), Verdeso(TM) and Luxiq(R).

Stiefel Laboratories, Inc. Completes Acquisition of Connetics ...  -  Dec 28, 2006
Yahoo! News (press release)Brevoxyl®Creamy Wash, Oilatum®, Soriatane®, Evoclin®, Verdeso(TM) and Luxiq®. Its wholly-owned global network is comprised of more than 30 subsidiaries,

Connetics Announces Results of Special Stockholders Meeting  -  Dec 20, 2006
Genetic Engineering News (press release),The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin)

Connetics Announces Results of Special Stockholders Meeting  -  Dec 20, 2006
Genetic Engineering News (press release),The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin)

Connetics Q3 Turns To Loss On Fall In Revenue - Update  09 Nov 2006
Product revenues include Soriatane sales of $10.4 million, OLUX sales of $4.3 million, Evoclin sales of $2.3 million and Luxiq sales of $1.8 million. ... -Trading Markets, Connetics Reports Third Quarter Financial Results  Nov 8, 2006
...quarter 2006 product revenues include Soriatane(R) sales of $10.4 million, OLUX(R) sales of $4.3 million, Evoclin(R) sales of $2.3 million and Luxiq(R) sales ... -Genetic Engineering News (press release), Stiefel to purchase Connetics  Oct 24, 2006
Cream with Sunscreens. Connetics sells Olux Foam, Luxiq Foam, Soriatane capsules, Evoclin Foam and Verdeso Foam. The company's development ... -San Antonio Business Journal, Stiefel Plans $640M Acquisition Of Dermatology Firm Connetics  Oct 23, 2006
The company turned its attention to such products as Olux (clobetasol propionate) and Luxiq (betamethasone valerate) foams, marketed for scalp dermatoses. ... -BioWorld Online, Connetics Corporation to Merge into Stiefel Laboratories  Oct 23, 2006
The Company's commercial products are OLUX® (clobetasol propionate) Foam, 0.05%; Luxiq® (betamethasone valerate) Foam, 0.12%; Soriatane® (acitretin) capsules ... -Yahoo! News (press release) Connetics Corporation and Stiefel Laboratories, Inc. Sign ...  Oct 23, 2006
The Company's commercial products are OLUX ® (clobetasol propionate) Foam, 0.05%; Luxiq ® (betamethasone valerate) Foam, 0.12%; Soriatane ® (acitretin ... -Business Wire (press release), FDA Approves Connetics' Verdeso Foam for the Treatment of Mild-to ...  Sep 20, 2006
Chief Executive Officer of Connetics, said, "We have established leading brands in the topical mid- and super-high potency steroid categories with Luxiq(R) and ... -PharmaLive.com

FDA Approves Connetics' Eczema Drug  Sep 20, 2006
Verdeso is the company's first low-potency steroid product. Connetics already markets Luxiq, a mid-potency drug, and Olux, a super-high potency drug. ... -Houston Chronicle

New Rogaine(R) Foam Features Connetics' Proprietary VersaFoam(R) ...  Sep 5, 2006
Connetics' VersaFoam-based products are OLUX(R) for scalp dermatoses and non-scalp psoriasis, Luxiq(R) Foam for scalp dermatoses and Evoclin(R) Foam for the ... -Business Wire

Connetics Reports Positive Results From Second Phase III Clinical ...  Aug 28, 2006
...proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone ... -Genetic Engineering News

Connetics Reports Positive Results From Second Phase III Clinical ...  29 Aug 2006
...proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone ... -PipelineReview.com

Connetics Reports Second Quarter Financial Results  Aug 14, 2006
Second quarter 2006 revenues include Soriatane(R) sales of $16.3 million, OLUX(R) sales of $12.2 million, Evoclin(R) sales of $9.3 million and Luxiq(R) sales ... -Business Wire

Connetics Reports New Option Grants Under Nasdaq Marketplace Rule ...  Aug 7, 2006
...proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone ... -Business Wire

Connetics warns on profit; shares plunge  Jul 10, 2006
The Palo Alto, California-based company, whose products include Olux and Luxiq for conditions such as scalp psoriasis, said it expected second quarter and full ... -Reuters

Connetics Announces Extension and Changes in Terms of Convertible ...  Jul 19, 2006
...proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone ... -Business Wire

CORRECTED - UPDATE 1-Connetics warns on profit; shares plunge  Jul 10, 2006
The Palo Alto, California-based, which makes drugs for the dermatology market such as Olux and Luxiq for scalp conditions such as scalp psoriasis, said ... -Reuters



Connetics Reports Preliminary Results for First Quarter 2006 ...  May 3, 2006
...of 2006 were $47.7 million, including Soriatane(R) sales of $19.0 million, OLUX(R) sales of $14.1 million, Evoclin(R) sales of $8.0 million and Luxiq(R) sales ... - PharmaLive.com

Connetics Names Sunil Patel Vice President, Corporate Development ...  May 9, 2006
...proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone ... - PharmaLive.com





Connetics Provides Information on Securities and Exchange ...  Apr 7, 2006
...proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone ... - PharmaLive.com

Connetics Files Citizen Petition for Soriatane With the FDA ...  Apr 3, 2006
...proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone ... - Genetic Engineering News



President leaves PediaMed after sales force sold  Feb 27, 2006
Connetics said the PediaMed group would begin selling Evoclin (clindamycin) Foam, 1 percent, a topical treatment for acne, and Luxiq (betamethasone valerate ... - Cincinnati Business Courier,

Connetics Reports Fourth Quarter Revenues of $41.3 Million and EPS ...  Jan 31, 2006
2005 product revenues included OLUX(R) sales of $14.7 million, Soriatane(R) sales of $13.6 million, Evoclin(TM) sales of $6.9 million and Luxiq(R) sales of ... - PharmaLive.com

Connetics Names Freddie Park Vice President, Intellectual Property ...  Feb 6, 2006
...proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone ... - Genetic Engineering News

Connetics Acquires PediaMed Sales Organization; Enters Pediatric ...  Jan 10, 2006
...sales meeting in early February, the group will begin selling Evoclin(TM) (clindamycin) Foam, 1%, a topical treatment for acne, and Luxiq(R) (betamethasone ... - Genetic Engineering News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional